In this interview at ESMO 2018, Marc Peeters talks to touchONCOLOGY about colorectal cancer tumour location and biomarkers. He explains that left-sided cancers have a better prognosis and suggests some possible reasons for this. Dr Peeters also discusses how the use of biomarkers has developed in the last 10 years and how treatment and prognosis can be guided using these biomarkers. This development is largely down to progress in technology, such as easier access to next generation sequencing, and the advent of liquid biopsies. Unfortunately, there are certain types of colorectal cancers with a poor prognosis, such as RAS- and BRAF-mutated tumours. There is still a need for biologics that can be added to standard chemotherapy in patients with these tumours.
1. What has been the most important recent therapeutic breakthrough in metastatic colorectal cancer? (0:11)
2. What is the prognostic significance of tumour location in colorectal cancer? (0:59)
3. What progress has been made in understanding the prognostic significance of molecular biomarkers in colorectal cancer? (1:45)
4. What are the most important unmet needs in colorectal cancer? (3:09)
5. What do you expect to be the highlights of this year’s ESMO congress? (4:21)
Speaker disclosures: Marc Peeters has nothing to disclose in relation to this interview.
Filmed at the European Society for Medical Oncology (ESMO) 2018 Congress, Munich, Germany, 19–23 October 2018.
Share this Video
Related Videos In Gastrointestinal Oncology
Jared Weiss, ESMO 2021: The Efficacy and Safety Findings of the KRYSTAL-1 Study
touchONCOLOGY joins Dr Jared Weiss (UNC Lineburger Comprehensive Cancer Care Center, Chapel Hill, NC, USA) at ESMO 2021 to discuss KRYSTAL-1: Adagrasib (MRTX849) as Monotherapy or Combined with Cetuximab (Cetux) in Patients (Pts) With Colorectal Cancer (CRC) Harboring a KRASG12C Mutation. Questions 1. What is the rationale for targeting KRAS tumour mutations in colorectal cancer? […]
Bruno Sangro, EASL ILC 2021: Early Phase Data on Checkpoint Inhibitors in HCC
It was lovely to meet with Dr Bruno Sangro (Clínica Universidad de Navarra, Pamplona, Spain) to talk about some of the early phase data presented at EASL 2021 around immune checkpoint inhibitors in the treatment of HCC. Questions Why are patients with Child-Pugh B liver function excluded from clinical trials, and what is their prognosis? […]
Elena Garralda, ASCO 2021: Favezelimab in Metastatic Colorectal Cancer
touchONCOLOGY joins Dr Elena Garralda (Vall d’Hebron Institute of Oncology, Barcelona, Spain) at ASCO 2021 to discuss favezelimab in metastatic colorectal cancer. The abstract ‘A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer (NCT02720068)’ (abstract number 3584) was presented at the 2021 ASCO […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!